US/UK/Canada

Share

Contacts

  • Anders Hedlund

    CEO


    Perpetua Medical AB, Knivstagatan 8, SE-753 23, UPPSALA, Sweden
    +46 18 500 101
    +46 70 952 09 12
    http://perpetuamedical.se

    • Links

    Pick a time period -
    Tags ( Active)

    Perpetua Medical has entered a letter of intent regarding the acquisition of a majority stake in ES-Medical AB

    Perpetua Medical AB (publ) ("Perpetua Medical") has entered a letter of intent with the shareholders of ES-Medical AB ("ES-Medical" or the "Company") regarding an investment in the Company and acquisition of shares in ES-Medical. Perpetua Medical’s ownership is intended to amount to 70 percent of the shares in the Company after the transaction, with an option to acquire the remaining 30 percent after three years.ES-Medical is an Uppsala-based company active in disinfection and repair of endoscopy and ultrasound probes. The Company also performs service of the proprietary product C-10

    Resolutions from the Annual General Meeting 2024 in Pepetua Medcial

    The annual general meeting of Perpetua Medical AB (publ) was held on 14 June 2024, at 10.00 a.m. in Clarion Hotel Gillet's premises at Dragarbrunnsgatan 23, Uppsala. The meeting decided on all proposed matters in accordance with the board's previously published proposal. Below is a summary of the main decisions that were made.The English translation of the resolutions is an unofficial translation of the Swedish original. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.   Annual report The Annual General Meeting

    Perpetua Medical is offered a loan facility of up to SEK 25 million

    Perpetua Medical AB (publ) is offered a loan facility of up to SEK 25 million from the company’s main shareholder, Nolsterby Invest AB, to be used for financing acquisitions.The company's main shareholder, Nolsterby Invest AB, has offered a loan facility of up to SEK 25 million under the terms described below, provided that the agreement is approved by an extraordinary general meeting (EGM), to be held no later than August 31, 2024. Nolsterby Invest AB is offering this loan facility to enable the company to make its first acquisitions under the company’s new business direction, as the

    Perpetua Medical publishes interim report January - March 2024

    Important milestones pave the way for a serial acquiring business. Perpetua Medical AB (publ) announces today that the interim report for the period January – March 2024 has been published. The interim report is attached as a PDF and is available on the company’s website:https://perpetuamedical.se/investor-relations-2/financial-reports/ (Swedish only). First Quarter January 1 – March 31 2024 · Consolidated net sales for the first quarter amounted to 1 373 (4 729) KSEK. · Operating profit for the first quarter amounted to SEK 2,041 (-4,299) KSEK. · Net earnings per share

    NOTICE OF ANNUAL GENERAL MEETING IN PERPETUA MEDICAL AB (PUBL)

    The shareholders of Perpetua Medical AB (publ), reg. no. 556723-6418 (the "Company"), are hereby noticed to attend the Annual General Meeting (the “AGM”) on June 14, 2024 at 11 AM at Clarion Hotel Gillet's premises, Dragarbrunnsgatan 23, Uppsala.Right to participate in the meeting Shareholders who wish to attend the annual general meeting must: · be registered in their own name (not nominee-registered) in the share register maintained by Euroclear Sweden AB on the record date for the meeting, which is Wednesday, June 5, 2024, · notify the Company of their participation so that

    Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) appoints Camilla Lönn as CFO

    Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) has appointed Camilla Lönn as the company’s new CFO.Camilla Lönn holds a degree in accounting from Uppsala University. She has extensive experience in roles in finance, accounting, and as a CFO, both as a consultant and as an employee. Camilla's recent roles have focused on smaller publicly traded companies, including assignments within the healthcare sector. Most recently, Camilla served as interim CFO for the First North listed company Brilliant Future AB. Erik Hedlund, Chairman of the Board and main owner of Perpetua Medical,

    Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) announces its first day of trading on Nasdaq First North under its new company name

    Perpetua Medical AB (formerly Pharmacolog i Uppsala AB) will start trading on Nasdaq First North Stockholm under the ticker PERP B today.Following the extraordinary general meeting’s resolution to adopt a new articles of association, the Swedish Companies Registration Office (Swe: Bolagsverket) has approved the company’s submission, after which Nasdaq has approved the application to change the name of the company. The first day of trading will take place today, April 23, 2024, under the ticker PERP B. The new name reflects the company’s ambition to be a long-term owner of profitable

    ANNOUNCEMENT FROM THE EXTRAORDINARY GENERAL MEETING OF PHARMACOLOG I UPPSALA AB ON APRIL 16, 2024

    Extraordinary General Meeting in Pharmacolog i Uppsala AB, reg. no. 556723-6418, (the "Company"), took place today, Wednesday, April 16, 2024, at 11.00 am at Clarion Hotell Gillet in Uppsala.All decisions were made in accordance with the Board's previously published proposal and with the required majority. Decisions new articles of association for the company It was resolved to change § 1 Company name in the articles of association to: "The company's company name is Perpetua Medical AB (publ). The company is public." In the event that the company name, for any reason, is not approved

    Pharmacolog announces the appointment of Anders Hedlund as interim CEO

    The Board has decided to appoint Anders Hedlund as interim CEO of the company. He replaces thereby Lars Gusch who will step down to pursue external opportunities as announced in an earlier press release. The replacement of CEO will be in effect from May 1, 2024.Anders Hedlund is currently the CEO of Nolsterby Invest AB, the largest shareholder in Pharmacolog. Nolsterby Invest AB is an investment company in the healthcare sector and has been invested in Pharmacolog since 2017. Since 2023, Anders Hedlund is also a current Board Member of Pharmacolog, a position he plans to maintain. Erik

    NOTICE TO EXTRAORDINARY GENERAL MEETING IN PHARMACOLOG I UPPSALA AB (PUBL)

    The shareholders of Pharmacolog i Uppsala AB (publ), reg. no. 556723-6418 (the "Company"), are hereby invited to an extraordinary general meeting on Tuesday, April 16, 2024 at 11:00 a.m. in Clarion Hotel Gillet's premises at Dragarbrunnsgatan 23, Uppsala.Right to attend the meeting Shareholders who wish to attend the meeting must: · be registered in their own name (not nominee registered) in the share register kept by Euroclear Sweden AB on the record date for the meeting, i.e. Monday, April 8, 2024, · notify the Company of their participation so that the notification is received

    Pharmacolog provides update on new business direction and proposes name change

    The Board of Directors has decided to proceed with the previously communicated business change. Against this background, Pharmacolog will convene an extraordinary general meeting in the manner prescribed by the Swedish Companies Act. The Board proposes a name change to Perpetua Medical AB (publ) and a new business direction, which includes the acquisition of smaller yet profitable companies in the healthcare sector. The background to this is that progress has been made regarding the investigation of a new business direction.In February, Pharmacolog announced that the Board intended to

    Pharmacolog announces upcoming change in management

    The company has decided by mutual agreement that Lars Gusch will step down from his current position as CEO on April 30, 2024.Pharmacolog announces that the currently appointed CEO Lars Gusch will step down from his position on April 30, 2024. This resignation is by mutual agreement with the Board of Directors, which in the meantime is working on the recruitment of a successor CEO, who will be announced in due course. Lars Gusch, CEO comments: "I would like to thank the Board of Directors for the trust they have placed in me and the good cooperation. Pharmacolog has gone through

    Warrants of series TO3 were subscribed to approximately 90.4 percent and Pharmacolog receives approximately SEK 2.3 million

    NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Pharmacolog i Uppsala AB (publ) (”Pharmacolog” or the ”Company”) announces today the outcome of the exercise of warrants of series TO3, which  were issued in connection with the Compan’'s rights issue of units on Nasdaq

    Major shareholder in Pharmacolog exercises warrants of series TO3 for at least approximately SEK 0.54 million

    NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. The major shareholder Nolsterby Invest AB, that is controlled by the board members Erik Hedlund and Anders Hedlund exercises, warrants of series TO3 in Pharmacolog i Uppsala AB (“Pharmacolog” or the “Company”). The

    The last day of trading with warrants of series TO3 in Pharmacolog is today, February 20, 2024

    NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Today, February 20, 2024, is the last day of trading with the warrants of series TO3 in Pharmacolog i Uppsala AB (“Pharmacolog” or the “Company”). The exercise period for the warrants of series TO3 continues until February

    Year-end bulletin Pharmacolog 2023

    Press release: Uppsala, February 16, 2024 Pharmacolog i Uppsala AB (publ) year-end bulletin for the period January - December 2023 is now available on the company's website  and is attached as a pdf.Fourth quarter October 1 - December 31, 2023 · The Group's net sales for the fourth quarter amounted to KSEK 2 567 (1 785). · Operating profit for the quarter amounted to KSEK -4,159 (-6,763). · Net earnings per share for the quarter were SEK -0.06 (-0.36) before dilution and SEK -0.03 (-0.31) after dilution. The

    Pharmacolog investigates the possibilities for a new business direction

    Within the framework of the Board's established strategy, a significant milestone was recently communicated with the sale of Druglog to Raysearch Laboratories AB. Together with the cost-saving measures implemented by the Board, the financial risk is reduced to the extent that the company's position can pave the way for a new business direction. The Board intends to immediately investigate the conditions for a new business direction, which may include the acquisition of niche and profitable companies in the life science sector.The work of looking for and identifying potential acquisitions

    Pharmacolog terminates the partnership agreement with Codonics with immediate effect

    Pharmacolog terminates the existing partnership agreement with Codonics Inc. with immediate effect due to insufficient sales performance.In December 2020, Pharmacolog AB and Codonics Inc. entered into a partnership agreement for sales and marketing of WasteLog™ for the North American market, which over time has been expanded to include sales of DrugLog™ and several regions, such as China, the Middle East region, the GCC countries and Jordan, Mexico and Canada. This agreement established minimum sales targets for the DrugLog™ and WasteLog™ products, which were not closely met for either

    Pharmacolog divests part of its operations to RaySearch Laboratories AB

    Pharmacolog AB (Publ) announces today that the company will divest it's product line Druglog™ to RaySearch Laboratories AB through a so-called asset acquisition. The total value of the transaction amounts to SEK 8.5 million, of which the cash consideration is SEK 7 million , which will be paid at the time of the closing. Through this transaction, Druglog™ gains new and better conditions to develop commercially within RaySearch, for the benefit of cancer patients and healthcare providers worldwide.During the fourth quarter of 2024, the Board of Directors of Pharmacolog implemented a strategy

    The exercise period for warrants of series TO3 begins today

    NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR IN ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ACTION OTHER THAN THAT REQUIRED BY SWEDISH LAW. Today, on February 9, 2024, the subscription period begins for the warrants of series TO3 in Pharmacolog i Uppsala AB (“Pharmacolog” or the “Company”). The subscription period runs until February 23, 2024.Summarized

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media